204 related articles for article (PubMed ID: 3078197)
1. [Use of the biostator for programming the insulin infusion pump Microjet-Bolus-2 in the treatment of insulin-dependent diabetes mellitus].
Sieradzki J; Szurkowska M
Pol Arch Med Wewn; 1988 May; 79(5):271-7. PubMed ID: 3078197
[No Abstract] [Full Text] [Related]
2. [Short-term subcutaneous infusion of insulin using a portable insulin pump in the treatment of diabetes mellitus].
Krzymień J; Szymerska E; Bak M; Regulski M; Tracz M
Pol Arch Med Wewn; 1989 Apr; 81(4):214-22. PubMed ID: 2626347
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of dawn phenomenon without change in insulin clearance in patients with insulin-dependent diabetes mellitus.
Campbell PJ; Gerich JE
Diabetes; 1986 Jul; 35(7):749-52. PubMed ID: 3522315
[TBL] [Abstract][Full Text] [Related]
4. [Use of the blood glucose-controlled Biostator for intravenous infusion of insulin for optimal insulin therapy (so-called corrective feedback)].
Sieradzki J; Szurkowska M
Pol Arch Med Wewn; 1986 Feb; 75(2):127-34. PubMed ID: 3748830
[No Abstract] [Full Text] [Related]
5. [An improvement in insulin efficacy in patients with type-1 diabetes mellitus following treatment using an insulin infusion pump].
Borisova AM; Koev D; Kirilov G
Vutr Boles; 1989; 28(1):74-7. PubMed ID: 2662610
[TBL] [Abstract][Full Text] [Related]
6. The use of technology to reduce hypoglycemia.
Choudhary P; Amiel SA
Pediatr Endocrinol Rev; 2010 Aug; 7 Suppl 3():384-95. PubMed ID: 20877251
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with optimized therapy of insulin dependent diabetes mellitus using NovoPen].
Carta G; Borgoglio A; Borgoglio MG; Granata L; Cordera R; Adezati L
Clin Ter; 1988 Feb; 124(4):315-20. PubMed ID: 2974343
[No Abstract] [Full Text] [Related]
8. [Use of the "Biostator" apparatus in patients with a labile course of diabetes mellitus].
Spesivtseva BG; Mamaeva GG; Seid-Guseĭnov AA; Turova EA; Leonova LN
Sov Med; 1983; (2):44-8. PubMed ID: 6344245
[No Abstract] [Full Text] [Related]
9. A randomized study comparing blood glucose control and risk of severe hypoglycemia achieved by non-programmable versus programmable external insulin pumps.
Catargi B; Breilh D; Gin H; Rigalleau V; Saux MC; Roger P; Tabarin A
Diabetes Metab; 2001 Jun; 27(3):323-7. PubMed ID: 11431597
[TBL] [Abstract][Full Text] [Related]
10. Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps.
Pickup JC
Diabetes Technol Ther; 2011 Jul; 13(7):695-8. PubMed ID: 21668344
[No Abstract] [Full Text] [Related]
11. Neonatal diabetes and insulin pump therapy.
Beardsall K; Pesterfield CL; Acerini CL
Arch Dis Child Fetal Neonatal Ed; 2011 May; 96(3):F223-4. PubMed ID: 21115555
[TBL] [Abstract][Full Text] [Related]
12. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
Liebl A; Hoogma R; Renard E; Geelhoed-Duijvestijn PH; Klein E; Diglas J; Kessler L; Melki V; Diem P; Brun JM; Schaepelynck-Bélicar P; Frei T;
Diabetes Obes Metab; 2009 Nov; 11(11):1001-8. PubMed ID: 19740082
[TBL] [Abstract][Full Text] [Related]
13. [Use of the biostator (artificial pancreas) in the treatment of patients with diabetes mellitus].
Spesivtseva VG; Mamaeva GG; Belokrinitskiĭ DV; Starosel'tseva LK; Turova EA
Klin Med (Mosk); 1984 Oct; 62(10):55-60. PubMed ID: 6513454
[No Abstract] [Full Text] [Related]
14. [Elimination of the instability of blood glucose level as a measure of increasing the effectiveness of insulin therapy in insulin-dependent diabetes mellitus].
Tikhonova EP
Ter Arkh; 1989; 61(2):81-4. PubMed ID: 2658195
[No Abstract] [Full Text] [Related]
15. Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study.
Franc S; Daoudi A; Pochat A; Petit MH; Randazzo C; Petit C; Duclos M; Penfornis A; Pussard E; Not D; Heyman E; Koukoui F; Simon C; Charpentier G
Diabetes Obes Metab; 2015 Dec; 17(12):1150-7. PubMed ID: 26264812
[TBL] [Abstract][Full Text] [Related]
16. Biostator Glucose Controller: a building block of the future.
Young A; Herf S
Diabetes Educ; 1984; 10(2):11-2. PubMed ID: 6378557
[No Abstract] [Full Text] [Related]
17. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial.
Tanenberg R; Bode B; Lane W; Levetan C; Mestman J; Harmel AP; Tobian J; Gross T; Mastrototaro J
Mayo Clin Proc; 2004 Dec; 79(12):1521-6. PubMed ID: 15595336
[TBL] [Abstract][Full Text] [Related]
18. Establishing Methods to Determine Clinically Relevant Bolus and Basal Rate Delivery Accuracy of Insulin Pumps.
Kamecke U; Waldenmaier D; Haug C; Ziegler R; Freckmann G
J Diabetes Sci Technol; 2019 Jan; 13(1):60-67. PubMed ID: 30003823
[TBL] [Abstract][Full Text] [Related]
19. [Insulin needs of insulin-dependent diabetics during biostator control and subcutaneous use of insulin].
Petkova M; Khristov V; Tsanev A
Vutr Boles; 1990; 29(1):74-7. PubMed ID: 2204207
[TBL] [Abstract][Full Text] [Related]
20. Predicting insulin requirements for a portable insulin pump using the Biostator. Evidence for reversible insulin resistance in poorly controlled type I diabetics.
Mayfield RK; Sullivan FM; Colwell JA; Wohltmann HJ
Diabetes; 1983 Oct; 32(10):908-14. PubMed ID: 6352376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
